FDA approves first drug for moderate and severe eczema cases

Mar 29, 2017 17:14 IST

The U.S. Food and Drug Administration (FDA) on 28 March 2017 approved Dupixent injection to treat adults with moderate-to-severe eczema (atopic dermatitis).

Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable.

The injection will have an initial list price of USD 37000 per year, as per Sanofi SA and Regeneron Pharmaceuticals, which developed the drug.

CA eBook

About Dupixent

Dupixent is administered as an injection under the skin.

The injection’s active ingredient is an antibody (dupilumab) that binds to a protein [interleukin-4 (IL-4) receptor alpha subunit (IL-4Ra)], that causes inflammation.

By binding to the protein, the drug is able to inhibit the inflammatory response that plays a role in the development of atopic dermatitis.

The safety and efficacy of the injection were established in three placebo-controlled clinical trials with a total of 2119 adult participants with moderate-to-severe atopic dermatitis not adequately controlled by topical medication.

About atopic dermatitis

Atopic dermatitis is a chronic inflammatory skin disease.

It is the most common of the many types of eczema.

Its cause is a combination of genetic, immune and environmental factors.

In atopic dermatitis, the skin develops red, scaly and crusted bumps, which are extremely itchy.

Is this article important for exams ? Yes
Read more Current Affairs on: Atopic Dermatitis , Eczema , FDA , Dupixent

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK